282 related articles for article (PubMed ID: 31852271)
1. Ovarian reserve markers in women using various hormonal contraceptives.
Landersoe SK; Forman JL; Birch Petersen K; Larsen EC; Nøhr B; Hvidman HW; Nielsen HS; Nyboe Andersen A
Eur J Contracept Reprod Health Care; 2020 Feb; 25(1):65-71. PubMed ID: 31852271
[No Abstract] [Full Text] [Related]
2. Ovarian reserve parameters: a comparison between users and non-users of hormonal contraception.
Bentzen JG; Forman JL; Pinborg A; Lidegaard Ø; Larsen EC; Friis-Hansen L; Johannsen TH; Nyboe Andersen A
Reprod Biomed Online; 2012 Dec; 25(6):612-9. PubMed ID: 23069740
[TBL] [Abstract][Full Text] [Related]
3. Ovarian reserve assessment in users of oral contraception seeking fertility advice on their reproductive lifespan.
Birch Petersen K; Hvidman HW; Forman JL; Pinborg A; Larsen EC; Macklon KT; Sylvest R; Andersen AN
Hum Reprod; 2015 Oct; 30(10):2364-75. PubMed ID: 26311148
[TBL] [Abstract][Full Text] [Related]
4. Anti-Müllerian hormone levels among contraceptive users: evidence from a cross-sectional cohort of 27,125 individuals.
Hariton E; Shirazi TN; Douglas NC; Hershlag A; Briggs SF
Am J Obstet Gynecol; 2021 Nov; 225(5):515.e1-515.e10. PubMed ID: 34126087
[TBL] [Abstract][Full Text] [Related]
5. Ovarian reserve markers and endocrine profile during oral contraception: Is there a link between the degree of ovarian suppression and AMH?
Landersoe SK; Larsen EC; Forman JL; Birch Petersen K; Kroman MS; Frederiksen H; Juul A; Nøhr B; Løssl K; Nielsen HS; Nyboe Andersen A
Gynecol Endocrinol; 2020 Dec; 36(12):1090-1095. PubMed ID: 32362164
[TBL] [Abstract][Full Text] [Related]
6. Hormonal and intrauterine methods for contraception for women aged 25 years and younger.
Krashin J; Tang JH; Mody S; Lopez LM
Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD009805. PubMed ID: 26280888
[TBL] [Abstract][Full Text] [Related]
7. Combined hormonal versus nonhormonal versus progestin-only contraception in lactation.
Lopez LM; Grey TW; Stuebe AM; Chen M; Truitt ST; Gallo MF
Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD003988. PubMed ID: 25793657
[TBL] [Abstract][Full Text] [Related]
8. Comparative pharmacokinetic analysis of levonorgestrel-releasing intrauterine systems and levonorgestrel-containing contraceptives with oral or subdermal administration route.
Hofmann BM; Apter D; Bitzer J; Reinecke I; Serrani M; Höchel J; Merz M
Eur J Contracept Reprod Health Care; 2020 Dec; 25(6):417-426. PubMed ID: 33006493
[TBL] [Abstract][Full Text] [Related]
9. Prediction value of anti-Mullerian hormone (AMH) serum levels and antral follicle count (AFC) in hormonal contraceptive (HC) users and non-HC users undergoing IVF-PGD treatment.
Bas-Lando M; Rabinowitz R; Farkash R; Algur N; Rubinstein E; Schonberger O; Eldar-Geva T
Gynecol Endocrinol; 2017 Oct; 33(10):797-800. PubMed ID: 28454495
[TBL] [Abstract][Full Text] [Related]
10. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.
Sturridge F; Guillebaud J
Drug Saf; 1996 Dec; 15(6):430-40. PubMed ID: 8968696
[TBL] [Abstract][Full Text] [Related]
11. A multicentre, open-label, randomised phase III study comparing a new levonorgestrel intrauterine contraceptive system (LNG-IUS 8) with combined oral contraception in young women of reproductive age.
Borgatta L; Buhling KJ; Rybowski S; Roth K; Rosen K
Eur J Contracept Reprod Health Care; 2016 Oct; 21(5):372-9. PubMed ID: 27494570
[TBL] [Abstract][Full Text] [Related]
12. Contraceptive-specific antimüllerian hormone values in reproductive-age women: a population study of 42,684 women.
Nelson SM; Ewing BJ; Gromski PS; Briggs SF
Fertil Steril; 2023 Jun; 119(6):1069-1077. PubMed ID: 36801456
[TBL] [Abstract][Full Text] [Related]
13. Ovarian reserve markers after discontinuing long-term use of combined oral contraceptives.
Landersoe SK; Birch Petersen K; Sørensen AL; Larsen EC; Martinussen T; Lunding SA; Kroman MS; Nielsen HS; Nyboe Andersen A
Reprod Biomed Online; 2020 Jan; 40(1):176-186. PubMed ID: 31831368
[TBL] [Abstract][Full Text] [Related]
14. Infertile women below the age of 40 have similar anti-Müllerian hormone levels and antral follicle count compared with women of the same age with no history of infertility.
Hvidman HW; Bentzen JG; Thuesen LL; Lauritsen MP; Forman JL; Loft A; Pinborg A; Nyboe Andersen A
Hum Reprod; 2016 May; 31(5):1034-45. PubMed ID: 26965431
[TBL] [Abstract][Full Text] [Related]
15. Assessment of Circulating Anti-Müllerian Hormone in Women Using Hormonal Contraception: A Systematic Review.
Amer SAKS; James C; Al-Hussaini TK; Mohamed AA
J Womens Health (Larchmt); 2020 Jan; 29(1):100-110. PubMed ID: 31314652
[No Abstract] [Full Text] [Related]
16. Ovarian function during hormonal contraception assessed by endocrine and sonographic markers: a systematic review.
D'Arpe S; Di Feliciantonio M; Candelieri M; Franceschetti S; Piccioni MG; Bastianelli C
Reprod Biomed Online; 2016 Oct; 33(4):436-448. PubMed ID: 27527655
[TBL] [Abstract][Full Text] [Related]
17. Risk of bacterial vaginosis, Trichomonas vaginalis and Candida albicans infection among new users of combined hormonal contraception vs LNG-IUS.
Rezk M; Sayyed T; Masood A; Dawood R
Eur J Contracept Reprod Health Care; 2017 Oct; 22(5):344-348. PubMed ID: 28849960
[TBL] [Abstract][Full Text] [Related]
18. Duration, recency, and type of hormonal contraceptive use and antimüllerian hormone levels.
Bernardi LA; Weiss MS; Waldo A; Harmon Q; Carnethon MR; Baird DD; Wise LA; Marsh EE
Fertil Steril; 2021 Jul; 116(1):208-217. PubMed ID: 33752880
[TBL] [Abstract][Full Text] [Related]
19. Antimüllerian hormone and antral follicle count are lower in female cancer survivors and healthy women taking hormonal contraception.
Johnson LN; Sammel MD; Dillon KE; Lechtenberg L; Schanne A; Gracia CR
Fertil Steril; 2014 Sep; 102(3):774-781.e3. PubMed ID: 24934488
[TBL] [Abstract][Full Text] [Related]
20. New knowledge in the physiology of hormonal contraceptives.
Lobo RA; Stanczyk FZ
Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1499-507. PubMed ID: 8178898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
